ns 2

Reproxalap (NS-2) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal. Reproxalap is a reactive aldehyde species sequestering agent for the treatment of the dry eye.

NS2B-NS3pro-IN-1, a potent Zika Virus NS2B-NS3 protease inhibitor, exhibits an EC50 of 50 μM and is significant in the ZIKV replication cycle [1].

Compound 11, also known as NS2B-NS3pro-IN-2, functions as an inhibitor of the Zika Virus NS2B-NS3 protease and exhibits antiviral properties at a concentration of 50 μM [1].

NS2 (114-121), Influenza, is a fragment derived from the nonstructural protein 2 (NS2) of the influenza virus. This compound serves as an epitope for influenza research and can be utilized to study the CD8+ cytotoxic T lymphocyte (CTL) in antiviral immune responses.

AFD-21 is a class I antiarrhythmic drug. It binds to sodium channels in their inactivated state and exerts use- and voltage-dependent inhibition of sodium channels with unbinding rates comparable to those of class I antiarrhythmic drugs with moderate kinetics.

Droxinostat (NS 41080) is a selective inhibitor of HDAC, mostly for HDACs 6 and 8 with IC50 of 2.47 μM and 1.46 μM, greater than 8-fold selective against HDAC3 and no inhibition to HDAC1, 2, 4, 5, 7, 9, and 10.

Hepatitis Virus C NS3 Protease Inhibitor 2 is a peptide inhibitor derived from a product that targets the NS3 protease of the hepatitis C virus (HCV). Its inhibitory activity against the NS3 protease is characterized by a Ki value of 41 nM.

NS2B/NS3-IN-5 (Compound 25b) is a variant of the DENV2 and ZIKV NS2B/NS3 protease inhibitor with IC50 values of 0.67 μM and 4.38 μM for the NS2B/NS3 protease of ZIKV and DENV2, respectively.

Compound 34e (NS2B/NS3-IN-4) is an allosteric inhibitor of the DENV2 and ZIKV NS2B/NS3 proteases, exhibiting IC50 values of 0.69 µM for DENV2 and 1.04 µM for ZIKV NS2B/NS3 proteases [1].

NS5A-IN-2 (Compound 33) serves as a potent NS5A inhibitor exhibiting exceptional efficacy against HCV genotype 1b, enhanced activity against genotype 3a (GT 3a), and notable metabolic stability [1].

NS2B/NS3-IN-2 is a potent, covalent inhibitor of dengue virus (DENV) NS2B/NS3 (IC50: 6.0 nM, Ki: 0.66 μM). NS2B/NS3-IN-2 significantly increases cell viability and is not cytotoxic.

NS2B/NS3-IN-3 hydrochloride is a Flavivirus NS2B-NS3 protease inhibitor [1].

NS2B/NS3-IN-7 is a highly potent inhibitor of the Zika virus NS2B-NS3 protease, possessing a Ki value of 2.33 nM. It effectively reduces the number of ZIKV-infected cells.

NS2B/NS3-IN-6 (Compound 1a) is a variant of the DENV and ZIKV NS2B/NS3 protease inhibitor with IC50 values of 2.23 μM and 25.2 μM for the NS2B/NS3 protease of ZIKV and DENV, respectively.

NS2B/NS3-IN-3 (Compd 66) is an inhibitor of Flavivirus NS2B-NS3 protease [1] .

NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide) is a COX-2 inhibitor wih anti-inflammatory activity.

NS-3-008 hydrochloride (NS-3-008 HCl) is a transcriptional G0 G1 switch 2 (G0s2) inhibitor( IC50 of 2.25 μM).

NS13001 (N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine) is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias.

NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs). NS3861 fumarate is a partial agonist at α3β4 nAChR and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively[1].

NS 11021 (NS11021) , a novel opener of large-conductance Ca(2+)-activated K(+) channels

NS-8, a pyrrole derivative, activates the calcium (Ca 2+)-sensitive potassium (K+)-channel, leading to the suppression of the micturition reflex through the reduction of afferent pelvic nerve activity. This compound is valuable for research into urinary frequency and incontinence.

Selexipag-d7 is a deuterated compound of Selexipag. Selexipag has a CAS number of 475086-01-2. Selexipag(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).

Selexipag (ACT-293987)(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).